Efficacy and safety of timolol-dorzolamide fixed-combination three times a day versus two times a day in newly diagnosed open-angle glaucoma.

Mohammad PakravanAfsaneh Naderi BeniShahin YazdaniHamed EsfandiariShahram Mirshojaee

Published in: Journal of drug assessment (2021)

Cosopt TDS has a superior IOP-lowering effect than Cosopt BID in POAG patients with comparable safety profiles.

Keyphrases